Develops oral drug candidates for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, with a lead candidate designed to deliver treatment to the lower intestine.
10-K for FY2025, filed Mar 20, 2026We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor…View ↗
Lead program
The older report centered on an oral digestive-enzyme inhibitor intended for use around surgery to prevent adhesions and improve bowel recovery. The latest report centers on an oral drug candidate for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 20, 2026Our lead therapeutic candidate, LB1148, is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic…View ↗
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (“PDE4”) inhibitor…View ↗
Competes with AbbVie, Johnson & Johnson, Eli Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Genentech, Teva, Morphic Therapeutic, Ventyx, and Spyre Therapeutics
10-K for FY2025, filed Mar 20, 2026If approved for the treatment of patients with moderate-to-severe IBD, our portfolio of products would compete with TNF antibodies…View ↗
Loading...